LL-37 (Cathelicidin): The Human Antimicrobial Peptide — What the Science Actually Shows
The human body produces its own natural antibiotics. One of the most powerful is LL-37 — a 37-amino acid peptide derived from cathelicidin, a class of host defense proteins found across mammals, birds, and fish.
LL-37 is the only cathelicidin peptide produced by humans, and it does far more than kill bacteria. It modulates the immune system, accelerates wound healing, combats biofilms, shows antiviral activity, and is being studied for its role in conditions ranging from chronic leg ulcers to cancer. Understanding LL-37 means understanding one of the body's most versatile and intelligent natural defense molecules.
What Is LL-37?
LL-37 is a cationic, amphipathic alpha-helical peptide consisting of 37 amino acids. It is derived from the proteolytic cleavage of hCAP18 (human cationic antimicrobial protein of 18 kDa), the precursor protein encoded by the CAMP gene on chromosome 3p21.3.
The "LL" designation refers to the two leucine residues at its N-terminus, and the "37" indicates its amino acid length.
LL-37 is produced by neutrophils (stored in specific granules and released during infection), macrophages and monocytes, epithelial cells of the skin, lungs, gut, and urogenital tract, as well as natural killer (NK) cells, mast cells, and dendritic cells. This broad distribution reflects LL-37's role as a frontline defense molecule — produced wherever the body interfaces with the external environment.
Mechanism of Action
Direct Antimicrobial Activity
The peptide carries a net positive charge (+6), which allows it to electrostatically attract to the negatively charged membranes of bacteria, fungi, and viruses. Once at the membrane surface, LL-37 inserts itself and disrupts the lipid bilayer through a "carpet model" — coating the membrane until it disintegrates from the inside out.
This physical disruption mechanism is critical: because LL-37 targets a structural feature (the membrane) rather than a specific enzyme or receptor, microbes cannot easily develop resistance through mutation. This makes it fundamentally different from most conventional antibiotics.
LL-37 has demonstrated activity against more than 38 bacterial species including Staphylococcus aureus (including MRSA), Pseudomonas aeruginosa, E. coli, and Mycobacterium tuberculosis; multiple viruses including influenza, HIV, SARS-CoV-2, and herpes simplex; fungi including Candida albicans; and parasites including Leishmania species.
Biofilm Disruption
One of LL-37's most clinically relevant properties is its ability to disrupt and prevent biofilms — communities of bacteria encased in a protective matrix that make them up to 1,000 times more resistant to conventional antibiotics. LL-37 disrupts quorum sensing (the bacterial communication system that triggers biofilm formation) and breaks down the extracellular polymeric substance matrix. This makes it particularly relevant for chronic wound infections, prosthetic joint infections, and catheter-associated infections.
Immune Modulation
Beyond direct killing, LL-37 acts as a chemoattractant for neutrophils, monocytes, and T-cells; modulates inflammatory cytokine production in a context-dependent manner; activates dendritic cells to bridge innate and adaptive immunity; neutralizes bacterial lipopolysaccharide (LPS), blunting the septic shock cascade; and promotes neutrophil extracellular trap (NET) formation that physically captures pathogens.
Wound Healing: The Most Developed Clinical Application
The most advanced clinical application of LL-37 is chronic wound healing, backed by human trial data.
LL-37 promotes healing through four distinct pathways: keratinocyte migration across wound surfaces (re-epithelialization), angiogenesis to supply healing tissue with blood, fibroblast activation to produce collagen and extracellular matrix, and controlled modulation of the inflammatory phase.
Critically, LL-37 is deficient in chronic non-healing ulcers. A landmark study found that venous leg ulcers that fail to heal show significantly reduced LL-37 expression compared to acute wounds and healthy skin — suggesting LL-37 deficiency may actively contribute to wound chronicity.
A Phase I/IIa randomized controlled trial (Grönberg et al., 2014) evaluated topical LL-37 in 34 patients with chronic venous leg ulcers. Patients receiving 0.5 mg/mL showed approximately 6-fold higher healing rate constants versus placebo; the 1.6 mg/mL group showed approximately 3-fold improvement. These findings established human proof-of-concept for LL-37 as a wound healing therapeutic.
Skin Health and Dermatological Conditions
LL-37 plays a complex — and sometimes contradictory — role in skin health. The same peptide that protects against skin infections can drive inflammatory skin disease at elevated concentrations.
Where deficiency causes problems: In atopic dermatitis (eczema), patients have significantly reduced LL-37 in affected skin, increasing susceptibility to Staphylococcus aureus colonization — a primary driver of eczema flares. In Netherton syndrome (a rare genetic disorder), impaired LL-37 processing leads to chronic skin infections.
Where overexpression drives disease: In rosacea, LL-37 is markedly overexpressed. Abnormal serine protease activity drives aberrant cleavage of hCAP18, producing LL-37 fragments that trigger vascular changes and inflammation. A 2025 study identified a Jak1/STAT1 signaling pathway mediating LL-37-driven T-cell recruitment in rosacea pathogenesis. In psoriasis, LL-37 forms complexes with self-DNA released from dying keratinocytes, activating plasmacytoid dendritic cells via TLR9 and triggering the interferon response that drives psoriatic inflammation.
This bidirectionality is essential: LL-37 is not simply "more is better." Context, concentration, and tissue type determine whether it protects or causes harm.
Antiviral Activity and the Vitamin D Connection
LL-37 shows meaningful antiviral activity against influenza (disrupts viral envelopes and reduces intracellular replication), SARS-CoV-2 (research has examined spike protein interactions), HIV (inhibits replication through membrane disruption and immune modulation), and herpes simplex (HSV-1 and HSV-2).
The vitamin D / LL-37 connection is fundamental: vitamin D is the primary transcriptional inducer of CAMP gene expression, which encodes the hCAP18/LL-37 precursor. Vitamin D binds directly to a vitamin D response element (VDRE) in the CAMP gene promoter, upregulating LL-37 production. This may be one of the most important mechanisms through which vitamin D supports immune function — and helps explain the consistent epidemiological link between vitamin D deficiency and increased susceptibility to respiratory and skin infections.
Practical implication: maintaining optimal vitamin D levels (25-OH-D > 40–60 ng/mL) is one of the most evidence-based ways to support endogenous LL-37 production without any synthetic peptide use.
Research-Grade Dosing Protocols
LL-37 is currently a research peptide and is not FDA-approved for systemic therapeutic use outside of clinical trials. The following reflects patterns observed in the research and peptide therapy communities.
⚠️ Disclaimer: LL-37 is not approved for general therapeutic use. This information is provided for educational purposes only. Consult a qualified physician before considering any peptide protocol.
Typical research protocols include subcutaneous injection at 100–200 mcg daily or 5 times per week for 4–8 weeks; intranasal administration at 50–100 mcg daily for 2–4 weeks for respiratory applications; and topical wound application at 0.5–1.6 mg/mL applied twice weekly for 4 weeks (the clinically-studied protocol).
Lower doses (100 mcg) are typically used for maintenance and general immune support. Higher doses (200–500 mcg) are explored for acute infection or wound healing. Cycling is recommended — continuous long-term use is not well-characterized in humans.
LL-37 is supplied lyophilized. Standard reconstitution uses bacteriostatic water — adding 1 mL to a 1 mg vial yields 1,000 mcg/mL, so a 100 mcg dose = 0.1 mL. Store lyophilized at -20°C (stable 12–24 months); reconstituted at 2–8°C, use within 30 days.
Safety Profile and Side Effects
Known side effects include injection site reactions (redness, swelling, mild burning — the most common adverse effect, related to LL-37's cationic charge recruiting local immune cells), transient fatigue or flushing at higher doses, and potential immune activation in individuals with autoimmune conditions.
Laboratory data shows LL-37 becomes cytotoxic to mammalian cells at approximately 1–10 µM (roughly 4.5–45 µg/mL), depending on cell type. Clinical and research protocols are designed to stay well below these thresholds.
LL-37 should be avoided by individuals with rosacea or psoriasis (where LL-37 overexpression already contributes to disease), those with active autoimmune conditions without physician oversight, and individuals with known cathelicidin hypersensitivity.
Current Research Directions (2025–2026)
LL-37 research is accelerating across several fronts. Modified analogs (truncated and retro-inverso variants) preserve antimicrobial activity while reducing cytotoxicity and improving protease stability — the primary pharmacological limitations of native LL-37. Nanoparticle delivery systems (liposomal and polymer-based) extend half-life and enable targeted delivery. Cancer research continues to investigate LL-37's context-dependent pro- or anti-tumor activity. Sepsis research explores its LPS-neutralizing and cytokine-modulating properties as potential adjunct therapy. Antibiotic synergy studies show LL-37 enhances the effectiveness of meropenem, nafcillin, and other antibiotics, potentially enabling lower doses and reduced resistance development.
Frequently Asked Questions
Can you boost LL-37 naturally?
Yes. Vitamin D is the primary natural upregulator — maintaining 25-OH-D levels above 40 ng/mL supports robust LL-37 production. Regular physical exercise and butyrate-producing dietary fiber also upregulate cathelicidin expression. Sunlight exposure (which drives vitamin D synthesis in skin) may be one of the oldest natural mechanisms for boosting LL-37.
Does LL-37 affect the gut microbiome?
While LL-37 targets pathogens, some preclinical studies show effects on commensal bacteria at high concentrations. Topical or targeted delivery minimizes this risk. Systemic administration warrants monitoring of gut health markers.
What is LL-37's half-life?
Native LL-37 has a relatively short plasma half-life due to proteolytic degradation. This is a primary driver behind research into modified analogs and protected delivery systems that extend activity.
How does LL-37 compare to defensins?
Both are human host defense peptides, but LL-37 has broader immunomodulatory effects, demonstrated wound healing activity in human trials, and broader antiviral coverage. Defensins (alpha and beta) are also important in innate immunity but have seen less clinical development to date.
Conclusion
LL-37 is one of the most multifunctional peptides in human biology — a single molecule that serves simultaneously as an antibiotic, antiviral, wound healer, immune recruiter, and inflammatory modulator. Its uniqueness as the only human cathelicidin gives it special significance in the study of innate immunity.
Its complexity — the same peptide that defends eczema-prone skin against Staphylococcus aureus also drives inflammatory cascades in rosacea — underscores that LL-37 is profoundly context-dependent. Concentration, tissue type, and health status all shape its effects.
For those interested in host defense peptides, infection biology, or the frontier of peptide therapeutics, LL-37 represents one of the richest research targets in modern biomedical science. Clinical development of optimized analogs and delivery systems is advancing rapidly, and the next decade is likely to yield the first approved LL-37-based therapeutics — beginning with chronic wounds and antibiotic-resistant infections.